Recent Press Releases

Roche launches Global Access Program for HIV viral load testing

Program expands access to care supporting the Diagnostics Access Initiative

PLEASANTON, Calif., Sept.

Universal Health Services, Inc. To Present At The Leerink Healthcare Services Roundtable

KING OF PRUSSIA, Pa., Sept. 25, 2014 /PRNewswire/ -- Universal Health Services, Inc.

IGI Laboratories acquires regulatory rights for 18 drug products from AstraZeneca

IGI Laboratories acquires regulatory rights for 18 drug products from AstraZeneca Published on September 25, 2014 IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic...

MannKind Announces Closing of Global Licensing Agreement With Sanofi

MannKind Announces Closing of Global Licensing Agreement With Sanofi VALENCIA, Calif., Sep 24, 2014 (GLOBE NEWSWIRE via COMTEX) -- MannKind Corporation MNKD, +0.49% today announced the closing of a...

Shire Pharmaceuticals LLC to Pay $56.5 Million to Resolve False Claims Act Allegations Relating to Drug Marketing and Promotion Practices

Pharmaceutical company Shire Pharmaceuticals LLC will pay $56.5 million to resolve civil allegations that it violated the False Claims Act as a result of its marketing and promotion of several drugs,...

ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise

WHIPPANY, N.J., Sept. 24, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.

Bristol-Myers Squibb to Build State-of-the-Art Campus in Lawrenceville, N.J.

Bristol-Myers Squibb to Build State-of-the-Art Campus in Lawrenceville, N.J. New campus will be located at intersection of Princeton Pike and Interstate 295 Construction is expected to begin this...

Amgen Submits Biologics License Application for Investigational BiTE® Immunotherapy Blinatumomab

FDA Submission Reinforces Commitment to Addressing Significant Unmet Needs for Patients With Acute Lymphoblastic Leukemia, an Aggressive Cancer With Limited Treatment Options

Endo International Comments On Auxilium Pharmaceutical's Rejection Of Its Acquisition Proposal

Endo International Comments On Auxilium Pharmaceutical's Rejection Of Its Acquisition Proposal DUBLIN, Sept. 22, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) today...

AUXILIUM PROVIDES TRANSACTION UPDATE

AUXILIUM PROVIDES TRANSACTION UPDATE Board Unanimously Reaffirms Recommendation of QLT Transaction CHESTERBROOK, Pa., Sept. 22, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a...

Bayer Receives Approval for EYLEA® for the Treatment of Myopic Choroidal Neovascularization in Japan

Bayer Receives Approval for EYLEA® for the Treatment of Myopic Choroidal Neovascularization in Japan Berlin, September 22, 2014 – Bayer HealthCare has received approval from the Ministry of...

Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal

Culinary Expert Visits San Diego County on September 20 to Help Educate At-Risk Population About Ingredients for Successful Blood Sugar Management

 

European Commission Grants Marketing Authorization for Gilead's Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

European Commission Grants Marketing Authorization for Gilead's Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma -- First-in-Class Oral Treatment...

FDA Approves Trulicity™ (dulaglutide), Lilly's Once-Weekly Therapy for Adults with Type 2 Diabetes

- Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise

CYRAMZA™ In Combination With Paclitaxel Significantly Improves Overall Survival In Second-Line Gastric Cancer Patients

-- Phase III RAINBOW Trial Data Published in The Lancet Oncology --

INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- Eli Lil

VIVUS AND AUXILIUM ANNOUNCE FDA APPROVAL OF STENDRA SNDA; STENDRA NOW FIRST AND ONLY ORAL ERECTILE DYSFUNCTION TREATMENT APPROVED TO BE TAKEN APPROXIMATELY 15 MINUTES BEFORE SEXUAL ACTIVITY

VIVUS AND AUXILIUM ANNOUNCE FDA APPROVAL OF STENDRA SNDA; STENDRA NOW FIRST AND ONLY ORAL ERECTILE DYSFUNCTION TREATMENT APPROVED TO BE TAKEN APPROXIMATELY 15 MINUTES BEFORE SEXUAL ACTIVITY MOUNTAIN...

CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies

CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies WOONSOCKET, R.I., Sept. 17, 2014 /PRNewswire/ -- An analysis done by the CVS Health Research Institute...

Bayer plans to focus entirely on Life Science businesses

Concentration on HealthCare and CropScience / MaterialScience to be floated on the stock market by 2016 at the latest / Planned separation to benefit both Bayer and MaterialScience / Employment...

Salix Secures Additional Intellectual Property Relating to Rifaximin

Salix Secures Additional Intellectual Property Relating to Rifaximin RALEIGH, N.C.--(BUSINESS WIRE)-- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that Cipla Limited has granted Salix...